Coronavirus: Pfizer, BioNTech get two vaccine candidates fast-tracked by US authorities

The two formulations showed positive results in early-stage trial data

Pfizer - Coronavirus: Pfizer, BioNTech get two vaccine candidates fast-tracked by US authorities

Pfizer Inc (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced two of their four COVID-19 vaccine candidates have been fast-tracked by the US Food and Drug Administration.

The BNT162b1 and BNT162b2 formulations are the most advanced in the programme, currently being evaluated in phase 1/2 clinical trials in the US and Germany.

READ: Pfizer and BioNTech shares jump as early data from coronavirus vaccine trial cheers investors

Early data released at the beginning of July showed 24 of 45 participants had 'significantly elevated' antibodies within four weeks of the first injection.

The fast-track designation facilitates the development and speeds up the review of new drugs and vaccines that have the potential to address an unmet medical need.

BioNTech shot up 9% to US$76.38 while Pfizer rose 2% to US$34.63 in premarket trading.

Quick facts: Pfizer

Price: 38.39 USD

Market: NYSE
Market Cap: $213.33 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Alpha Growth PLC’s Danny Swick and Austin King describe the BlackOak Alpha...

Alpha Growth PLC (LON: ALGW) Chief Operations Officer Danny Swick and Investor Relations Officer Austin King joined Steve Darling from Proactive with news the company has started their BlackOak Alpha Growth Fund which is their life settlement investment fund geared toward U.S. investors. Both...

1 hour, 13 minutes ago

2 min read